Picture of Eris Lifesciences logo

ERIS — Eris Lifesciences News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareBalancedMid CapFalling Star

India's Biocon falls; Kotak says Eris deal valuation below expectations

** Biocon  BION.NS  drops ~5% and is the top pct loser on
Nifty pharma index  .NIPHARM , which is down 1.5%
    ** BION shares rose 5.8% on Thurs on saying unit Biocon
Biologics will sell its branded formulations business to Eris
Lifesciences  ERIS.NS  for 12.42 bln rupees ($150 mln)
    ** Brokerage Kotak says the deal value was below its
expectations; keeps "reduce" rating"
    ** Eris stock down 2.5%, after gaining 3.8% on Thurs
    ** Kotak says despite ~10% drop in net debt post deal,
BION's leverage (net debt to EBITDA at 2.8X even in FY26)
remains a key concern
    ** Avg rating of 17 analysts on BION is "hold" -LSEG data

 (Reporting by Kashish Tandon in Bengaluru)
 ((kashish.tandon@thomsonreuters.com))

Recent news on Eris Lifesciences

See all news